征祥医药赴港IPO，资产负债率高达416%

Core Viewpoint - Zhengxiang Pharmaceutical (Nanjing) Group Co., Ltd. has submitted an application for a mainboard listing, with its core product expected to launch in October 2025, while currently facing a high debt-to-equity ratio of 416% [1]. Group 1: Company Overview - Zhengxiang Pharmaceutical is a biopharmaceutical company established in 2018, focusing on the discovery, development, and commercialization of innovative therapies for unmet medical needs in viral infectious diseases, oncology, and inflammatory diseases [1]. - The company's core product, Marcilosavir tablets, is a targeted inhibitor of the influenza virus polymerase acidic protein (PA) and has received NDA approval for treating adult influenza [1]. Group 2: Financial Performance - For the reporting periods of 2024 and the first three quarters of 2025, the company's revenue was RMB 0 and RMB 355,000, primarily from providing drug registration assistance to Cigalah Medpharm [4]. - The company reported losses of RMB 145.395 million for both 2024 and 2025, with an increase in losses compared to RMB 126.729 million in the first three quarters of 2024 [4][6]. Group 3: Debt and Financial Risks - As of the end of Q3 2025, the total liabilities of the company were approximately RMB 1.26 billion, with a net debt of about RMB 956.4 million, resulting in a debt-to-equity ratio of 415.84% [6][7]. - The company has faced negative operating cash flow, with net cash used in operating activities amounting to RMB 106 million and RMB 91 million for the respective reporting periods [6]. - The company has highlighted potential liquidity and financial risks due to its net debt situation, which may require seeking external funding sources [7].